The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 25, 2022
Filed:
Dec. 20, 2018
Applicant:
Biogen Swiss Manufacturing Gmbh, Baar, CH;
Inventors:
Henrik Nilsson, Dubai, AE;
Bernd W. Mueller, Flintbek, DE;
Assignee:
Biogen Swiss Manufacturing GmbH, Baar, CH;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/225 (2006.01); A61K 9/28 (2006.01); A61K 45/06 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01); A61K 31/215 (2006.01); A61K 31/22 (2006.01); A61K 9/50 (2006.01); A61K 9/14 (2006.01); A61K 9/16 (2006.01); A61K 9/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/225 (2013.01); A61K 9/0053 (2013.01); A61K 9/14 (2013.01); A61K 9/167 (2013.01); A61K 9/20 (2013.01); A61K 9/2013 (2013.01); A61K 9/2027 (2013.01); A61K 9/2031 (2013.01); A61K 9/2054 (2013.01); A61K 9/2077 (2013.01); A61K 9/2081 (2013.01); A61K 9/28 (2013.01); A61K 9/2846 (2013.01); A61K 9/2853 (2013.01); A61K 9/2866 (2013.01); A61K 9/48 (2013.01); A61K 9/4808 (2013.01); A61K 9/4891 (2013.01); A61K 9/50 (2013.01); A61K 9/5042 (2013.01); A61K 9/5047 (2013.01); A61K 9/5084 (2013.01); A61K 31/215 (2013.01); A61K 31/22 (2013.01); A61K 45/06 (2013.01);
Abstract
The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.